Results 11 to 20 of about 19,663 (194)
Interaction between crizotinib and tropifexor through in vitro and in vivo studies [PDF]
PeerJIn the context of cancer treatment, the employment of multiple drug therapies frequently results in a high prevalence of drug-drug interaction (DDI) in clinical practice.
An Shen +5 more
doaj +3 more sources
Translational Oncology, 2019 INTRODUCTION: C-Met plays important roles in treatment resistance, tumor invasion, and metastasis. In this study, we used a small molecule inhibitor of c-Met, crizotinib, in cetuximab-resistant, mutant KRAS-driven colorectal cancer cell lines and ...
Kyle C. Cuneo +5 more
doaj +2 more sources
Lung Cancer: Targets and Therapy, 2016 Etienne Giroux Leprieur,1,2 Vincent Fallet,3,4 Jacques Cadranel,3,4 Marie Wislez3,4 1Respiratory Diseases and Thoracic Oncology Department, APHP-Ambroise Paré Hospital, Boulogne-Billancourt, France; 2EA4340 Laboratory, UVSQ, Paris-Saclay ...
Giroux Leprieur E +3 more
doaj +1 more source
Substituent Effects of Heptamethine Cyanine Dyes on Drug Uptake in Patient-Derived Glioma Cells. [PDF]
ChemMedChemGlioblastoma (GBM) remains difficult to treat primarily due to tumor heterogeneity and the presence of the blood–brain barrier (BBB). This study demonstrates the in vitro activity of the pan‐kinase inhibitor crizotinib conjugated to BBB‐penetrating heptamethine cyanine dyes with diverse functional groups across four patient‐derived GBM cell lines ...
Dumo CJ +7 more
europepmc +2 more sources
First-Line Lorlatinib in Striatin-Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma: A Case Report and Literature Review. [PDF]
Respirol Case RepA 45‐year‐old male with STRN–ALK‐positive lung adenocarcinoma and brain metastases achieved a significant and durable response to first‐line lorlatinib. Together with our literature review of 15 previously reported cases, this case supports further evaluation of lorlatinib as a first‐line treatment option for patients harbouring this rare ALK fusion ...
Maebeya M +4 more
europepmc +2 more sources
Development of Renal Cysts after Crizotinib Treatment in Advanced ALK-Positive Non-Small-Cell Lung Cancer [PDF]
, 2017 Introduction: The development of complex renal cysts after crizotinib treatment for non-small-cell lung cancer (NSCLC) is a reported side effect. However, its occurrence and characteristics have not been reported.
楊志新;楊泮池;余忠仁;林奕廷;吳尚俊;施金元;王郁棻 +1 more
core +2 more sources
Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged nonsmall cell lung cancer and beyond [PDF]
, 2011 Sai-Hong Ignatius OuChao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, CAAbstract: Epidermal growth factor receptor (EGFR) tyrosine inhibitors were first approved for the treatment of non-small cell lung ...
Ou SH, Sai-Hong Ignatius Ou
core +1 more source
CAQ Corner: Basic concepts of transplant immunology
, 2022 Liver Transplantation, EarlyView.
Amanda Cheung, Josh Levitsky
wiley +1 more source
Cancer Reports, 2021 Background Most patients treated with anaplastic lymphoma kinase (ALK)‐tyrosine kinase inhibitors for ALK‐positive non‐small cell lung cancer (NSCLC) develop resistance, leading to metastasis, with progression to the central nervous system (CNS) being a ...
Hiroaki Sakamoto +12 more
doaj +1 more source
First-Line Crizotinib versus Chemotherapy inALK-Positive Lung Cancer [PDF]
, 2014 BACKGROUND: The efficacy of the ALK inhibitor crizotinib as compared with standard chemotherapy as first-line treatment for advanced ALK-positive non-small-cell lung cancer (NSCLC) is unknown.
Wu, Yi-Long +15 more
core +4 more sources